What does the new study showing a link between low-dose hormonal contraceptives and breast cancer really tell us in practical terms? First, that the risk has not gone away with the introduction of pills delivering newer and lower formulations, and second, that the risk is significant at the population level but tiny at the individual level. It is important to unpack the study’s findings to really put them into perspective.
Coming in early 2018 is a new one-dose oral treatment for bacterial vaginosis (BV). The drug’s effectiveness is similar to that of the metronidazole, a treatment currently recommended by the Centers for Disease Control and Prevention, but with an ease of use that may enhance adherence to treatment regimen.
Have you read the headlines that the incidence of oropharyngeal cancer in men has outpaced the incidence of cervical cancer in women? Further, that the prevalence of oropharyngeal cancer in men has doubled over the past 20 years? All true. But the headlines make the situation appear more dire than it currently is. However, without action, the situation could eventually become a dire public health threat. There is an important role for women’s reproductive health providers to play in containing the threat of an epidemic of HPV-related throat cancer.
The “Contraceptive Technology” conferences will help you synthesize the data and translate the evidence into clinical “pearls” you can put directly into practice. With an array of Preconferences delving into selected specialty areas of interest, plenary sessions focusing on the “hottest” topics, a thought-provoking luncheon presentation, and 30 dynamic, interactive Concurrent Sessions, including hands-on workshops…this conference is certain to improve your clinical practice and expand your network of colleagues. Read more